Back

Characterization of Critical Determinants of ACE2-RBD Interaction

Brown, E. E. F.; Rezaei, R.; Jamieson, T.; Dave, J.; Martin, N. T.; Singaravelu, R.; Crupi, M. J. F.; Boulton, S.; Tucker, S.; Duong, J.; Poutou, J.; Pelin, A.; Yasavoli-Sharahi, H.; Taha, Z.; Arulanandam, R.; Surendran, A.; Ghahremani, M.; Austin, B.; Matar, C.; Diallo, J.-S.; Bell, J. C.; Ilkow, C. S.; Azad, T.

2021-01-29 microbiology
10.1101/2021.01.29.428773 bioRxiv
Show abstract

Despite sequence similarity to SARS-CoV-1, SARS-CoV-2 has demonstrated greater widespread virulence and unique challenges to researchers aiming to study its pathogenicity in humans. The interaction of the viral receptor binding domain (RBD) with its main host cell receptor, angiotensin-converting enzyme 2 (ACE2), has emerged as a critical focal point for the development of anti-viral therapeutics and vaccines. Utilizing our recently developed NanoBiT technology-based biosensor, we selectively identify and characterize the impact of mutating certain amino acid residues in the RBD of SARS-CoV-2 and in ACE2. Specifically, we examine the mutational effects on RBD-ACE2 binding ability, before and after the addition of competitive inhibitors, as well as neutralizing antibody activity. These critical determinants of virus-host interactions may provide more effective targets for ongoing vaccines, drug development, and potentially pave the way for determining the genetic variation underlying disease severity.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.